Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)-Reference-Cited by-同舟云学术

Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE)

Published:2019-06-03 Issue:6 Volume:54 Page:718-725
ISSN:0036-5521
Container-title:Scandinavian Journal of Gastroenterology
language:en
Short-container-title:Scandinavian Journal of Gastroenterology

Author:

Eberl Anja¹,Hallinen Taru²,af Björkesten Clas-Göran¹,Heikkinen Markku³,Hirsi Eija⁴,Kellokumpu Mikko⁵,Koskinen Inka⁶,Moilanen Veikko⁷,Nielsen Christian⁸,Nuutinen Heikki⁹,Suhonen Ulla-Maija¹⁰,Utriainen Karri¹¹,Vihriälä Ilkka¹²,Soini Erkki²,Wennerström Christina¹³¹⁴,Nissinen Riikka¹⁵,Borsi Andras¹⁶,Koivunen Minni¹⁵,Tillonen Jyrki¹⁷,Sipponen Taina¹

Affiliation:

1. Gastroenterology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland;

2. ESiOR Oy, Kuopio, Finland;

3. Department of Internal Medicine, Kuopio University Hospital, Kuopio, Finland;

4. Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland;

5. Department of Internal Medicine, Lapland Central Hospital, Rovaniemi, Finland;

6. Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä, Finland;

7. Department of Internal Medicine, Satakunta Central Hospital, Pori, Finland;

8. Department of Internal Medicine, Vaasa Central Hospital, Vaasa, Finland;

9. Division of Gastroenterology, Department of Medicine, Turku University Hospital, Turku, Finland;

10. Department of Internal Medicine, Kainuu Central Hospital, Kajaani, Finland;

11. Division of Gastroenterology, Department of Medicine, Turku University Hospital/Salo Hospital, Salo, Finland;

12. Department of Internal Medicine, Central Ostrobothnia Central Hospital Kokkola, Finland;

13. Medical Affairs, Janssen Cilag AB Solna, Sweden;

14. Department of Epidemiology Research, Statens Serum Institut, Denmark Copenhagen;

15. Medical Affairs, Janssen Cilag Oy, Espoo Finland;

16. Janssen Cilag Limited, EMEA HEMAR, High Wycombe, United Kingdom;

17. Department of Internal Medicine, Päijät Häme Central Hospital, Lahti Finland

Publisher

Informa UK Limited

Subject

Gastroenterology

Link

https://tandfonline.com/doi/pdf/10.1080/00365521.2019.1624817

Reference29 articles.

1. Crohn's disease

2. Thiopurines and inflammatory bowel disease: Current evidence and a historical perspective

3. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease

4. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management

5. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease;Journal of Clinical Medicine;2024-01-24

2. A Narrative Review of Cytokine Networks: Pathophysiological and Therapeutic Implications for Inflammatory Bowel Disease Pathogenesis;Biomedicines;2023-12-06

3. Dose Escalation Patterns of Advanced Therapies in Crohn’s Disease and Ulcerative Colitis: A Systematic Literature Review;Advances in Therapy;2023-03-17

4. Systematic Review and Meta-Analysis of Observational Studies on the Effectiveness and Safety of Ustekinumab among Patients with Inflammatory Bowel Disease in Eastern and Western Countries;Journal of Clinical Medicine;2023-02-27

5. Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study;Intestinal Research;2023-01-31